Healthcare - Biotechnology - NASDAQ - US
$ 3.99
-3.39 %
$ 178 M
Market Cap
-1.27
P/E
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor.[ Read More ]
The intrinsic value of one VSTM stock under the base case scenario is HIDDEN Compared to the current market price of 3.99 USD, Verastem, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart VSTM
FINANCIALS
0
REVENUE
-92.1 M
OPERATING INCOME
-87.4 M
NET INCOME
-86.5 M
OPERATING CASH FLOW
-44.4 M
INVESTING CASH FLOW
134 M
FINANCING CASH FLOW
0
REVENUE
-37 M
OPERATING INCOME
-24 M
NET INCOME
-23.8 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
53.6 M
FINANCING CASH FLOW
Balance Sheet Decomposition
Verastem, Inc.
| Current Assets | 144 M |
| Cash & Short-Term Investments | 137 M |
| Receivables | 0 |
| Other Current Assets | 6.55 M |
| Non-Current Assets | 6.04 M |
| Long-Term Investments | 241 K |
| PP&E | 1.21 M |
| Other Non-Current Assets | 4.59 M |
| Current Liabilities | 26.4 M |
| Accounts Payable | 7.18 M |
| Short-Term Debt | 1.88 M |
| Other Current Liabilities | 17.3 M |
| Non-Current Liabilities | 44.8 M |
| Long-Term Debt | 40.6 M |
| Other Non-Current Liabilities | 4.19 M |
EFFICIENCY
Earnings Waterfall
Verastem, Inc.
| Revenue | 0 |
| Cost Of Revenue | 62 K |
| Gross Profit | -62 K |
| Operating Expenses | 92.1 M |
| Operating Income | -92.1 M |
| Other Expenses | -4.72 M |
| Net Income | -87.4 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-152.28%
ROE
-58.35%
ROA
-93.58%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Verastem, Inc.
| Net Income | -87.4 M |
| Depreciation & Amortization | -113 K |
| Capital Expenditures | 7 K |
| Stock-Based Compensation | 5.86 M |
| Change in Working Capital | -957 K |
| Others | -4.84 M |
| Free Cash Flow | -86.5 M |
Wall Street Analysts Price Targets
Verastem, Inc.
Wall Street analysts predict an average 1-year price target for VSTM of $9 , with forecasts ranging from a low of $5 to a high of $13 .
VSTM Lowest Price Target
Wall Street Target
5 USD
25.31%
VSTM Average Price Target
Wall Street Target
9 USD
125.56%
VSTM Highest Price Target
Wall Street Target
13 USD
225.81%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Verastem, Inc.
Sold
0-3 MONTHS
8.38 K USD 4
3-6 MONTHS
13.3 K USD 4
6-9 MONTHS
18.4 K USD 4
9-12 MONTHS
240 K USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 week ago
Nov 05, 2024
|
Sell 3.12 K USD
|
Paterson Dan
President and CEO |
- 812
|
3.84 USD |
|
1 month ago
Oct 07, 2024
|
Sell 17.2 USD
|
Calkins Daniel
Chief Financial Officer |
- 6
|
2.86 USD |
|
1 month ago
Sep 20, 2024
|
Sell 182 USD
|
Calkins Daniel
Chief Financial Officer |
- 65
|
2.8 USD |
|
1 month ago
Sep 24, 2024
|
Sell 75 USD
|
Calkins Daniel
Chief Financial Officer |
- 28
|
2.68 USD |
|
1 month ago
Sep 19, 2024
|
Sell 365 USD
|
Gagnon Robert E.
Director |
- 131
|
2.79 USD |
|
1 month ago
Sep 19, 2024
|
Sell 513 USD
|
Paterson Dan
President and CEO |
- 184
|
2.79 USD |
|
1 month ago
Sep 19, 2024
|
Sell 937 USD
|
Stuglik Brian M
Director |
- 336
|
2.79 USD |
|
2 months ago
Sep 16, 2024
|
Sell 804 USD
|
Gagnon Robert E.
Director |
- 287
|
2.8 USD |
|
2 months ago
Sep 16, 2024
|
Sell 1.68 K USD
|
Stuglik Brian M
Director |
- 600
|
2.8 USD |
|
2 months ago
Sep 16, 2024
|
Sell 689 USD
|
Paterson Dan
President and CEO |
- 246
|
2.8 USD |
|
3 months ago
Aug 05, 2024
|
Sell 7.01 K USD
|
Paterson Dan
President and CEO |
- 3245
|
2.16 USD |
|
4 months ago
Jul 09, 2024
|
Sell 18.3 USD
|
Calkins Daniel
Chief Financial Officer |
- 7
|
2.62 USD |
|
4 months ago
Jun 24, 2024
|
Sell 88.2 USD
|
Calkins Daniel
Chief Financial Officer |
- 28
|
3.15 USD |
|
4 months ago
Jun 20, 2024
|
Sell 212 USD
|
Calkins Daniel
Chief Financial Officer |
- 67
|
3.16 USD |
|
4 months ago
Jun 20, 2024
|
Sell 421 USD
|
Gagnon Robert E.
Director |
- 131
|
3.21 USD |
|
5 months ago
Jun 17, 2024
|
Sell 988 USD
|
Gagnon Robert E.
Director |
- 283
|
3.49 USD |
|
4 months ago
Jun 20, 2024
|
Sell 587 USD
|
Paterson Dan
President and CEO |
- 183
|
3.21 USD |
|
5 months ago
Jun 17, 2024
|
Sell 852 USD
|
Paterson Dan
President and CEO |
- 244
|
3.49 USD |
|
4 months ago
Jun 20, 2024
|
Sell 1.08 K USD
|
Stuglik Brian M
Director |
- 335
|
3.21 USD |
|
5 months ago
Jun 17, 2024
|
Sell 2.07 K USD
|
Stuglik Brian M
Director |
- 593
|
3.49 USD |
|
7 months ago
Apr 05, 2024
|
Sell 65.2 USD
|
Calkins Daniel
Chief Financial Officer |
- 6
|
10.87 USD |
|
7 months ago
Mar 25, 2024
|
Sell 300 USD
|
Calkins Daniel
Chief Financial Officer |
- 25
|
12.02 USD |
|
7 months ago
Mar 20, 2024
|
Sell 609 USD
|
Calkins Daniel
Chief Financial Officer |
- 55
|
11.07 USD |
|
8 months ago
Mar 18, 2024
|
Sell 3.03 K USD
|
Gagnon Robert E.
Director |
- 283
|
10.71 USD |
|
7 months ago
Mar 19, 2024
|
Sell 1.35 K USD
|
Gagnon Robert E.
Director |
- 130
|
10.38 USD |
|
8 months ago
Mar 18, 2024
|
Sell 2.61 K USD
|
Paterson Dan
President and CEO |
- 244
|
10.71 USD |
|
7 months ago
Mar 19, 2024
|
Sell 1.89 K USD
|
Paterson Dan
President and CEO |
- 182
|
10.38 USD |
|
8 months ago
Mar 18, 2024
|
Sell 5.75 K USD
|
Stuglik Brian M
Director |
- 537
|
10.71 USD |
|
7 months ago
Mar 19, 2024
|
Sell 2.83 K USD
|
Stuglik Brian M
Director |
- 273
|
10.38 USD |
|
9 months ago
Feb 06, 2024
|
Sell 126 K USD
|
Gagnon Robert E.
Director |
- 9204
|
13.7 USD |
|
7 years ago
Sep 05, 2017
|
Bought 7.68 K USD
|
Rowinsky Eric K
Director |
+ 2000
|
3.84 USD |
|
10 months ago
Jan 12, 2024
|
Sell 101 K USD
|
Gagnon Robert E.
Director |
- 9204
|
10.95 USD |
|
10 months ago
Jan 05, 2024
|
Sell 51 USD
|
Calkins Daniel
Chief Financial Officer |
- 6
|
8.5 USD |
|
10 months ago
Dec 26, 2023
|
Sell 202 USD
|
Calkins Daniel
Chief Financial Officer |
- 25
|
8.08 USD |
|
10 months ago
Dec 20, 2023
|
Sell 452 USD
|
Calkins Daniel
Chief Financial Officer |
- 57
|
7.93 USD |
|
11 months ago
Dec 18, 2023
|
Sell 2.17 K USD
|
Gagnon Robert E.
Director |
- 284
|
7.64 USD |
|
10 months ago
Dec 19, 2023
|
Sell 1 K USD
|
Gagnon Robert E.
Director |
- 130
|
7.73 USD |
|
11 months ago
Dec 18, 2023
|
Sell 1.86 K USD
|
Paterson Dan
President and CEO |
- 244
|
7.64 USD |
|
10 months ago
Dec 19, 2023
|
Sell 1.41 K USD
|
Paterson Dan
President and CEO |
- 183
|
7.73 USD |
|
11 months ago
Dec 18, 2023
|
Sell 3.72 K USD
|
Stuglik Brian M
Director |
- 487
|
7.64 USD |
|
10 months ago
Dec 19, 2023
|
Sell 2.12 K USD
|
Stuglik Brian M
Director |
- 274
|
7.73 USD |
|
1 year ago
Oct 05, 2023
|
Sell 36.5 USD
|
Calkins Daniel
Vice President of Finance |
- 5
|
7.3 USD |
|
1 year ago
Sep 21, 2023
|
Sell 2.16 K USD
|
Calkins Daniel
Vice President of Finance |
- 232
|
9.31 USD |
|
1 year ago
Sep 25, 2023
|
Sell 235 USD
|
Calkins Daniel
Vice President of Finance |
- 25
|
9.4 USD |
|
1 year ago
Sep 18, 2023
|
Sell 2.38 K USD
|
Paterson Dan
President and CEO |
- 240
|
9.91 USD |
|
1 year ago
Sep 19, 2023
|
Sell 1.8 K USD
|
Paterson Dan
President and CEO |
- 183
|
9.84 USD |
|
1 year ago
Sep 18, 2023
|
Sell 2.75 K USD
|
Gagnon Robert E.
Director |
- 278
|
9.91 USD |
|
1 year ago
Sep 19, 2023
|
Sell 1.28 K USD
|
Gagnon Robert E.
Director |
- 130
|
9.84 USD |
|
1 year ago
Sep 18, 2023
|
Sell 4.74 K USD
|
Stuglik Brian M
Director |
- 478
|
9.91 USD |
|
1 year ago
Sep 19, 2023
|
Sell 2.7 K USD
|
Stuglik Brian M
Director |
- 274
|
9.84 USD |
|
1 year ago
Jul 06, 2023
|
Sell 40.1 USD
|
Calkins Daniel
Vice President of Finance |
- 5
|
8.02 USD |
|
1 year ago
Jun 26, 2023
|
Sell 212 USD
|
Calkins Daniel
Vice President of Finance |
- 26
|
8.17 USD |
|
1 year ago
Jun 16, 2023
|
Sell 2.42 K USD
|
Paterson Dan
President and COO |
- 244
|
9.92 USD |
|
1 year ago
Jun 20, 2023
|
Sell 1.88 K USD
|
Paterson Dan
President and COO |
- 183
|
10.3 USD |
|
1 year ago
Jun 16, 2023
|
Sell 2.81 K USD
|
Gagnon Robert E.
Director |
- 283
|
9.92 USD |
|
1 year ago
Jun 20, 2023
|
Sell 1.34 K USD
|
Gagnon Robert E.
Director |
- 130
|
10.3 USD |
|
1 year ago
Jun 16, 2023
|
Sell 4.83 K USD
|
Stuglik Brian M
Chief Executive Officer |
- 487
|
9.92 USD |
|
1 year ago
Jun 20, 2023
|
Sell 2.83 K USD
|
Stuglik Brian M
Chief Executive Officer |
- 275
|
10.3 USD |
|
1 year ago
Apr 05, 2023
|
Sell 27.8 USD
|
Calkins Daniel
Vice President of Finance |
- 75
|
0.37 USD |
|
1 year ago
Mar 24, 2023
|
Sell 159 USD
|
Calkins Daniel
Vice President of Finance |
- 378
|
0.42 USD |
|
1 year ago
Mar 16, 2023
|
Sell 1.46 K USD
|
Gagnon Robert E.
Director |
- 3654
|
0.4 USD |
|
1 year ago
Mar 20, 2023
|
Sell 716 USD
|
Gagnon Robert E.
Director |
- 1664
|
0.43 USD |
|
1 year ago
Mar 16, 2023
|
Sell 1.26 K USD
|
Paterson Dan
President and COO |
- 3138
|
0.4 USD |
|
1 year ago
Mar 20, 2023
|
Sell 1.01 K USD
|
Paterson Dan
President and COO |
- 2339
|
0.43 USD |
|
1 year ago
Mar 16, 2023
|
Sell 2.51 K USD
|
Stuglik Brian M
Chief Executive Officer |
- 6276
|
0.4 USD |
|
1 year ago
Mar 20, 2023
|
Sell 1.51 K USD
|
Stuglik Brian M
Chief Executive Officer |
- 3508
|
0.43 USD |
|
1 year ago
Jan 05, 2023
|
Sell 31.8 USD
|
Calkins Daniel
Vice President of Finance |
- 74
|
0.43 USD |
|
1 year ago
Dec 27, 2022
|
Sell 411 USD
|
Calkins Daniel
Vice President of Finance |
- 1246
|
0.33 USD |
|
1 year ago
Dec 16, 2022
|
Sell 6.27 K USD
|
Paterson Dan
President and COO |
- 15676
|
0.4 USD |
|
1 year ago
Dec 19, 2022
|
Sell 1.09 K USD
|
Paterson Dan
President and COO |
- 2954
|
0.37 USD |
|
1 year ago
Dec 16, 2022
|
Sell 4.96 K USD
|
Gagnon Robert E.
Director |
- 12408
|
0.4 USD |
|
1 year ago
Dec 19, 2022
|
Sell 529 USD
|
Gagnon Robert E.
Director |
- 1429
|
0.37 USD |
|
1 year ago
Dec 16, 2022
|
Sell 10.1 K USD
|
Stuglik Brian M
Chief Executive Officer |
- 25162
|
0.4 USD |
|
1 year ago
Dec 19, 2022
|
Sell 1.32 K USD
|
Stuglik Brian M
Chief Executive Officer |
- 3556
|
0.37 USD |
|
2 years ago
Sep 19, 2022
|
Sell 3.79 K USD
|
Stuglik Brian M
Chief Executive Officer |
- 3355
|
1.13 USD |
|
2 years ago
Sep 19, 2022
|
Sell 1.52 K USD
|
Gagnon Robert E.
Chief Financial Officer |
- 1348
|
1.13 USD |
|
2 years ago
Aug 01, 2022
|
Sell 6.33 K USD
|
Stuglik Brian M
Chief Executive Officer |
- 5858
|
1.08 USD |
|
2 years ago
Jun 21, 2022
|
Sell 3.08 K USD
|
Paterson Dan
President and COO |
- 2701
|
1.14 USD |
|
2 years ago
Jun 21, 2022
|
Sell 3.83 K USD
|
Stuglik Brian M
Chief Executive Officer |
- 3362
|
1.14 USD |
|
2 years ago
Jun 21, 2022
|
Sell 1.54 K USD
|
Gagnon Robert E.
Chief Financial Officer |
- 1351
|
1.14 USD |
|
2 years ago
May 14, 2022
|
Sell 5.14 K USD
|
Paterson Dan
President and COO |
- 4988
|
1.03 USD |
|
2 years ago
May 14, 2022
|
Sell 14.2 K USD
|
Stuglik Brian M
Chief Executive Officer |
- 13794
|
1.03 USD |
|
2 years ago
May 14, 2022
|
Sell 17.1 K USD
|
Gagnon Robert E.
Chief Financial Officer |
- 16627
|
1.03 USD |
|
2 years ago
May 02, 2022
|
Sell 8.26 K USD
|
Stuglik Brian M
Chief Executive Officer |
- 5857
|
1.41 USD |
|
2 years ago
Mar 21, 2022
|
Sell 3.58 K USD
|
Paterson Dan
President and COO |
- 2818
|
1.27 USD |
|
2 years ago
Mar 21, 2022
|
Sell 4.45 K USD
|
Stuglik Brian M
Chief Executive Officer |
- 3507
|
1.27 USD |
|
2 years ago
Mar 21, 2022
|
Sell 1.79 K USD
|
Gagnon Robert E.
Chief Financial Officer |
- 1409
|
1.27 USD |
|
2 years ago
Jan 31, 2022
|
Sell 8.43 K USD
|
Stuglik Brian M
Chief Executive Officer |
- 5695
|
1.48 USD |
|
2 years ago
Jan 03, 2022
|
Sell 53.4 K USD
|
Stuglik Brian M
Chief Executive Officer |
- 26033
|
2.05 USD |
|
2 years ago
Jan 03, 2022
|
Sell 40.2 K USD
|
Gagnon Robert E.
Chief Financial Officer |
- 19612
|
2.05 USD |
|
2 years ago
Jan 03, 2022
|
Sell 48.2 K USD
|
Paterson Dan
President and COO |
- 23534
|
2.05 USD |
|
2 years ago
Dec 20, 2021
|
Sell 31.1 K USD
|
Stuglik Brian M
Chief Executive Officer |
- 13682
|
2.27 USD |
|
2 years ago
Dec 20, 2021
|
Sell 25 K USD
|
Paterson Dan
President and COO |
- 10994
|
2.27 USD |
|
2 years ago
Dec 20, 2021
|
Sell 12.5 K USD
|
Gagnon Robert E.
Chief Financial Officer |
- 5497
|
2.27 USD |
|
3 years ago
Dec 04, 2020
|
Bought 108 K USD
|
BARBERICH TIMOTHY J
Director |
+ 50000
|
2.17 USD |
|
4 years ago
Jun 25, 2020
|
Sell 2.22 M USD
|
RA CAPITAL MANAGEMENT, L.P.
10 percent owner |
- 1161300
|
1.9116 USD |
|
4 years ago
Apr 27, 2020
|
Sell 3 M USD
|
RA CAPITAL MANAGEMENT, L.P.
10 percent owner |
- 1301300
|
2.307 USD |
|
5 years ago
Mar 15, 2019
|
Bought 106 K USD
|
BARBERICH TIMOTHY J
Director |
+ 33000
|
3.21 USD |
|
6 years ago
Sep 28, 2018
|
Bought 36.6 K USD
|
BARBERICH TIMOTHY J
Director |
+ 5000
|
7.31 USD |
|
6 years ago
Sep 28, 2018
|
Bought 21.9 K USD
|
Lobacki Joseph M
Executive VP & CCO |
+ 3000
|
7.3 USD |
|
6 years ago
Sep 28, 2018
|
Bought 21 K USD
|
Paterson Dan
Chief Operating Officer |
+ 3000
|
7 USD |
|
6 years ago
Sep 28, 2018
|
Bought 14 K USD
|
Forrester Robert
President and CEO |
+ 2000
|
7 USD |
|
6 years ago
Sep 28, 2018
|
Bought 30 K USD
|
Kauffman Michael
Director |
+ 4000
|
7.49 USD |
|
6 years ago
Sep 28, 2018
|
Bought 4.38 K USD
|
Stuglik Brian M
Director |
+ 600
|
7.3 USD |
|
6 years ago
Sep 28, 2018
|
Bought 730 USD
|
Stuglik Brian M
Director |
+ 100
|
7.3 USD |
|
6 years ago
Sep 28, 2018
|
Bought 2.19 K USD
|
Stuglik Brian M
Director |
+ 300
|
7.31 USD |
|
6 years ago
Sep 27, 2018
|
Bought 70 K USD
|
Forrester Robert
President and CEO |
+ 10000
|
7 USD |
|
6 years ago
Sep 27, 2018
|
Bought 3.5 K USD
|
Forrester Robert
President and CEO |
+ 500
|
7 USD |
|
6 years ago
Sep 27, 2018
|
Bought 8.45 K USD
|
Paterson Dan
Chief Operating Officer |
+ 1200
|
7.04 USD |
|
6 years ago
Sep 27, 2018
|
Bought 5.61 K USD
|
Paterson Dan
Chief Operating Officer |
+ 800
|
7.01 USD |
|
6 years ago
Jun 08, 2018
|
Bought 44.6 K USD
|
Lobacki Joseph M
Executive VP & CCO |
+ 7700
|
5.79 USD |
|
6 years ago
Jun 08, 2018
|
Bought 17.9 K USD
|
Bloom Steven H.
Chief Strategy Officer |
+ 3000
|
5.98 USD |
|
6 years ago
Dec 05, 2017
|
Bought 239 K USD
|
BARBERICH TIMOTHY J
Director |
+ 60538
|
3.95 USD |
|
7 years ago
May 15, 2017
|
Bought 73.5 K USD
|
BARBERICH TIMOTHY J
Director |
+ 30000
|
2.45 USD |
|
9 years ago
Mar 19, 2015
|
Sell 10.2 K USD
|
Kauffman Michael
Director |
- 930
|
10.959 USD |
|
9 years ago
Aug 24, 2015
|
Sell 13.4 K USD
|
Kauffman Michael
Director |
- 2070
|
6.461 USD |
|
9 years ago
Jun 29, 2015
|
Bought 6.95 K USD
|
Singh Monica
General Counsel |
+ 1000
|
6.95 USD |
|
9 years ago
Jun 29, 2015
|
Bought 3.56 K USD
|
GREEN JOHN B
Chief Financial Officer |
+ 500
|
7.12 USD |
|
9 years ago
Jun 29, 2015
|
Bought 14.2 K USD
|
Forrester Robert
President and CEO |
+ 2000
|
7.105 USD |
|
9 years ago
Jun 26, 2015
|
Bought 3.7 K USD
|
GREEN JOHN B
Chief Financial Officer |
+ 500
|
7.3919 USD |
|
9 years ago
Jun 18, 2015
|
Bought 8.04 K USD
|
Paterson Dan
Chief Operating Officer |
+ 1000
|
8.045 USD |
|
9 years ago
Jun 17, 2015
|
Bought 7.97 K USD
|
Forrester Robert
President and CEO |
+ 1000
|
7.97 USD |
|
9 years ago
Jan 28, 2015
|
Bought 250 K USD
|
BARBERICH TIMOTHY J
Director |
+ 38462
|
6.5 USD |
|
9 years ago
Jan 28, 2015
|
Bought 8 M USD
|
Westphal Christoph H
Executive Chairman |
+ 1230769
|
6.5 USD |
|
9 years ago
Dec 23, 2014
|
Bought 122 K USD
|
TERMEER HENRI A
Director |
+ 15000
|
8.1083 USD |
|
9 years ago
Dec 23, 2014
|
Bought 114 K USD
|
TERMEER HENRI A
Director |
+ 14000
|
8.1078 USD |
|
9 years ago
Dec 29, 2014
|
Bought 85.4 K USD
|
Phanstiel S. Louise
Director |
+ 10000
|
8.5435 USD |
|
9 years ago
Dec 29, 2014
|
Bought 6.45 K USD
|
Horobin Joanna
Chief Medical Officer |
+ 750
|
8.6 USD |
|
9 years ago
Dec 26, 2014
|
Bought 21.4 K USD
|
SHERWIN STEPHEN A
Director |
+ 2500
|
8.558 USD |
|
9 years ago
Dec 24, 2014
|
Bought 24.9 K USD
|
FRIEDMAN PAUL A
Director |
+ 3000
|
8.3108 USD |
|
9 years ago
Dec 23, 2014
|
Bought 72.8 K USD
|
TERMEER HENRI A
Director |
+ 9000
|
8.0888 USD |
|
9 years ago
Dec 23, 2014
|
Bought 81.7 K USD
|
TERMEER HENRI A
Director |
+ 10100
|
8.0938 USD |
|
9 years ago
Dec 23, 2014
|
Bought 4.08 K USD
|
GREEN JOHN B
Chief Financial Officer |
+ 500
|
8.17 USD |
|
9 years ago
Dec 23, 2014
|
Bought 8.09 K USD
|
Singh Monica
General Counsel |
+ 1000
|
8.089 USD |
|
9 years ago
Dec 19, 2014
|
Bought 12.8 K USD
|
Westphal Christoph H
Executive Chairman |
+ 1500
|
8.5 USD |
|
9 years ago
Dec 19, 2014
|
Bought 17 K USD
|
Paterson Dan
Chief Operating Officer |
+ 2000
|
8.5199 USD |
|
9 years ago
Dec 19, 2014
|
Bought 8.66 K USD
|
Forrester Robert
President and CEO |
+ 1000
|
8.66 USD |
|
10 years ago
Nov 11, 2014
|
Bought 22.9 K USD
|
Lawton Alison Frances
Director |
+ 2500
|
9.1692 USD |
|
10 years ago
Sep 17, 2014
|
Bought 27.3 K USD
|
Kauffman Michael
Director |
+ 3000
|
9.0999 USD |
|
10 years ago
May 30, 2014
|
Bought 9.9 K USD
|
BARBERICH TIMOTHY J
Director |
+ 1000
|
9.895 USD |
|
10 years ago
May 20, 2014
|
Bought 8.37 K USD
|
ALDRICH RICHARD
Director |
+ 1000
|
8.37 USD |
|
10 years ago
May 15, 2014
|
Bought 7.47 K USD
|
Paterson Dan
Chief Business Officer |
+ 1000
|
7.467 USD |
|
10 years ago
May 14, 2014
|
Bought 15.1 K USD
|
Westphal Christoph H
Executive Chairman |
+ 2000
|
7.56 USD |
|
10 years ago
May 13, 2014
|
Bought 7.74 K USD
|
GREEN JOHN B
Chief Financial Officer |
+ 1000
|
7.74 USD |
|
10 years ago
May 13, 2014
|
Bought 7.62 K USD
|
Pachter Jonathan
VP, Head of Research |
+ 1000
|
7.62 USD |
|
10 years ago
May 13, 2014
|
Bought 7.62 K USD
|
Forrester Robert
President and CEO |
+ 1000
|
7.62 USD |
|
11 years ago
Nov 18, 2013
|
Bought 9.6 K USD
|
Westphal Christoph H
director, 10 percent owner: |
+ 1000
|
9.602 USD |
|
11 years ago
Nov 11, 2013
|
Bought 10.9 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
10.93 USD |
|
11 years ago
Nov 04, 2013
|
Bought 10.5 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
10.51 USD |
|
11 years ago
Oct 28, 2013
|
Bought 11.3 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
11.26 USD |
|
11 years ago
Oct 21, 2013
|
Bought 12.6 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
12.57 USD |
|
11 years ago
Oct 14, 2013
|
Bought 10.6 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
10.56 USD |
|
11 years ago
Oct 07, 2013
|
Bought 11.5 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
11.53 USD |
|
11 years ago
Sep 30, 2013
|
Bought 12.6 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
12.55 USD |
|
11 years ago
Sep 23, 2013
|
Bought 13.2 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
13.17 USD |
|
11 years ago
Sep 16, 2013
|
Bought 13.8 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
13.81 USD |
|
11 years ago
Sep 09, 2013
|
Bought 14 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
14.04 USD |
|
11 years ago
Sep 03, 2013
|
Bought 14.1 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
14.07 USD |
|
11 years ago
Aug 26, 2013
|
Bought 14.2 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
14.21 USD |
|
11 years ago
Aug 19, 2013
|
Bought 13.4 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
13.45 USD |
|
11 years ago
Aug 12, 2013
|
Bought 14.8 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
14.75 USD |
|
11 years ago
Aug 05, 2013
|
Bought 15.2 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
15.25 USD |
|
11 years ago
Jul 29, 2013
|
Bought 15.2 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
15.15 USD |
|
11 years ago
Jul 24, 2013
|
Bought 16.4 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
16.39 USD |
|
11 years ago
Jul 15, 2013
|
Bought 17.2 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
17.19 USD |
|
11 years ago
Jul 08, 2013
|
Bought 14.7 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
14.69 USD |
|
11 years ago
Jul 01, 2013
|
Bought 14.1 K USD
|
ALDRICH RICHARD
director, 10 percent owner: |
+ 1000
|
14.11 USD |
|
11 years ago
Jun 13, 2013
|
Bought 11.4 K USD
|
Forrester Robert
President and COO |
+ 1000
|
11.394 USD |
|
11 years ago
Jun 12, 2013
|
Bought 222 K USD
|
CHP III LP
10 percent owner |
+ 23171
|
9.5993 USD |
|
11 years ago
Jun 11, 2013
|
Bought 230 K USD
|
CHP III LP
10 percent owner |
+ 25000
|
9.2191 USD |
|
11 years ago
Jun 12, 2013
|
Bought 222 K USD
|
CLARKE JOHN K
Director |
+ 23171
|
9.5993 USD |
|
11 years ago
Jun 12, 2013
|
Bought 43.2 K USD
|
Phanstiel S. Louise
Director |
+ 4500
|
9.6005 USD |
|
11 years ago
Jun 12, 2013
|
Bought 56.7 K USD
|
TERMEER HENRI A
Director |
+ 5823
|
9.7443 USD |
|
11 years ago
Jun 11, 2013
|
Bought 75 K USD
|
Phanstiel S. Louise
Director |
+ 8000
|
9.3722 USD |
|
11 years ago
Jun 10, 2013
|
Bought 36.6 K USD
|
Phanstiel S. Louise
Director |
+ 4000
|
9.1625 USD |
|
11 years ago
Jun 11, 2013
|
Bought 230 K USD
|
CLARKE JOHN K
Director |
+ 25000
|
9.2191 USD |
|
11 years ago
Jun 11, 2013
|
Bought 106 K USD
|
TERMEER HENRI A
Director |
+ 11356
|
9.3537 USD |
|
11 years ago
Jun 07, 2013
|
Bought 9.06 K USD
|
Westphal Christoph H
Chief Executive Officer |
+ 1000
|
9.056 USD |
|
11 years ago
May 21, 2013
|
Bought 7.39 K USD
|
Westphal Christoph H
Chief Executive Officer |
+ 800
|
9.2412 USD |
|
11 years ago
May 13, 2013
|
Bought 243 K USD
|
CLARKE JOHN K
Director |
+ 25000
|
9.735 USD |
|
11 years ago
May 13, 2013
|
Bought 243 K USD
|
CHP III LP
10 percent owner |
+ 25000
|
9.735 USD |
|
11 years ago
May 03, 2013
|
Bought 7.86 K USD
|
Westphal Christoph H
Chief Executive Officer |
+ 800
|
9.8281 USD |
|
11 years ago
May 01, 2013
|
Bought 96.6 K USD
|
CLARKE JOHN K
Director |
+ 10000
|
9.6622 USD |
|
11 years ago
May 01, 2013
|
Bought 96.6 K USD
|
CHP III LP
10 percent owner |
+ 10000
|
9.662 USD |
|
11 years ago
Apr 17, 2013
|
Bought 53.5 K USD
|
CLARKE JOHN K
Director |
+ 5631
|
9.499 USD |
|
11 years ago
Apr 17, 2013
|
Bought 7.62 K USD
|
Westphal Christoph H
Chief Executive Officer |
+ 800
|
9.53 USD |
|
11 years ago
Apr 17, 2013
|
Bought 53.5 K USD
|
CHP III LP
10 percent owner |
+ 5631
|
9.499 USD |
|
11 years ago
Mar 21, 2013
|
Bought 7.23 K USD
|
Westphal Christoph H
Chief Executive Officer |
+ 800
|
9.04 USD |
|
11 years ago
Mar 05, 2013
|
Bought 7.58 K USD
|
Westphal Christoph H
Chief Executive Officer |
+ 800
|
9.47 USD |
|
11 years ago
Jan 29, 2013
|
Bought 3 K USD
|
Westphal Christoph H
Chief Executive Officer |
+ 300
|
10 USD |
|
11 years ago
Jan 02, 2013
|
Bought 7.78 K USD
|
Westphal Christoph H
President and C.E.O. |
+ 800
|
9.73 USD |
|
11 years ago
Dec 18, 2012
|
Bought 48.7 K USD
|
CHP III LP
10 percent owner |
+ 6193
|
7.87 USD |
|
11 years ago
Dec 18, 2012
|
Bought 48.7 K USD
|
CLARKE JOHN K
Director |
+ 6193
|
7.87 USD |
|
12 years ago
Jan 27, 2012
|
Bought 48.7 K USD
|
CHP III LP
10 percent owner |
+ 6193
|
7.87 USD |
7. News
Verastem Oncology to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in the following upcoming investor conferences: 2024 Truist Securities BioPharma Symposium on November 7, 2024 Guggenheim Healthcare Innovation Conference; fireside chat on Wednesday, November 13, 2024 at 9:00 am EDT A live webcast of the fireside chat can be accessed under “Events & Pr.
businesswire.com
- 2 weeks ago
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced updated data from the Phase 2 RAMP 201 (ENGOTov60/GOG3052) clinical trial evaluating the combination of avutometinib, an oral RAF/MEK clamp, and defactinib, an oral, selective FAK inhibitor, in patients with recurrent low-grade serous ovarian cancer (LGSOC). The data were published as a late-breaking abstract and additional detaile.
businesswire.com
- 1 month ago
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced further details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) clinical trial to be presented as an oral presentation at a plenary session at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting taking place October 16-18, 2024 in Dublin, Ireland. The l.
businesswire.com
- 1 month ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 109,000 shares of its common stock to nine new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options h.
businesswire.com
- 1 month ago
Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18 at 3:40 pm EDT. A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors & Media section of the company's website at www.verastem.com. A replay of.
businesswire.com
- 2 months ago
Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity
Verastem's Avutometinib and Defactinib combination therapy targets recurrent LGSOC and is expected to complete its rolling NDA by 2H2024. The company has a diverse pipeline, exploring treatments for metastatic pancreatic cancer and mKRAS G12C non-small cell lung cancer (NSCLC). Interim results for Avutometinib + Defactinib show a 45% ORR overall and 60% ORR for KRAS-mutant patients, with tumor regression in 86%.
seekingalpha.com
- 2 months ago
Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024
BOSTON & HOUSTON, Texas--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, and the STAAR Ovarian Cancer Foundation today announced the first Low-Grade Serous Ovarian Cancer Awareness Day or “LGSOC Awareness Day” on September 9, 2024. September is Ovarian Cancer Awareness Month and LGSOC is a rare ovarian cancer with little information and awareness available to patients and caregivers. This newly created.
businesswire.com
- 2 months ago
Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants
BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants to purchase common stock in lieu of common stock for certain investors and accompanying warrants to purchase shares of common stock, in an underwritten public offering. The pre-f.
businesswire.com
- 3 months ago
Verastem (VSTM) Begins Dosing in Solid Tumors Study in China
Verastem (VSTM) doses the first patient in a phase I/II study conducted by GenFleet Therapeutics, evaluating KRAS G12D inhibitor, GFH375/VS-7375 in solid tumors. Shares rise.
zacks.com
- 4 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. ("Verastem" or the "Company") (NASDAQ:VSTM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
accesswire.com
- 4 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. (“Verastem” or the “Company”) (NASDAQ: VSTM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
globenewswire.com
- 4 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
NEW YORK , July 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. ("Verastem" or the "Company") (NASDAQ: VSTM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
prnewswire.com
- 4 months ago
8. Profile Summary
Verastem, Inc. VSTM
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 178 M
Dividend Yield
0.00%
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Contact
117 Kendrick Street, Needham, MA, 02494
https://www.verastem.com
IPO Date
Jan. 27, 2012
Employees
73
Officers
Dr. Robert A. Weinberg Ph.D.
Co-Founder & Chair of Scientific Advisory Board
Mr. Nate Sanburn
Chief Business Officer
Mr. Daniel W. Paterson
President, Chief Executive Officer & Director
Mr. Michael Crowther
Chief Commercial & Strategy Officer
Mr. Daniel Calkins
Chief Financial Officer and Principal Accounting & Financial Officer
Ms. Cathy Carew
Chief Organizational Effectiveness Officer
Dr. Michelle Dipp M.D., Ph.D.
Co-Founder
Mr. Richard H. Aldrich M.B.A.
Founder and Consultant
Dr. Jonathan Pachter Ph.D.
Chief Scientific Officer
Dr. Piyush B. Gupta Ph.D.
Co-Founder